Established 1999
123jump.com - U.S. Financial Information Archive: 90,000 Annual and 10-K reports – 20,000 Global news stories - 3,500 IPO reports - 1,700 - Earnings Calls – 320 Fund Interviews – 10-year Annual earnings on 4,500 stocks – 20 Quarterly earnings on 3,600 stocks – 1,800 IPO prospectuses – 1,200 Economic data releases
     
   
 
  Quotes Find Symbol:
 Company Links
6 Cedar Brook Drive
Cranbury, NJ 08512
USA
+1-609-662-2000
http://www.amicustherapeutics.com/
 Management    Source: Company documents
Name : Donald J. Hayden
Title : Chairman of the Board
Since: 03/2006
Name : John F. Crowley
Title : President, Chief Executive Officer, Director
Since: 01/2005
Name : James Dentzer
Title : Chief Financial Officer
Since: 09/006
Name : Matthew R. Patterson
Title : Chief Operating Officer
Since: 09/2006
Name : Karin Ludwig
Title : Senior Vice President - Clinical Research
Since: 02/2006
Name : David Palling
Title : Senior Vice President - Drug Development
Since: 08/2002
Name : David J. Lockhart
Title : Chief Scientific Officer
Since: 01/2006
Name : Douglas A. Branch
Title : Vice President, General Counsel, Secretary
Since: 12/2005
Name : S. Nicole Schaeffer
Title : Vice President - Human Resources and Leadership Development
Since: 03/2005
Name : Gregory P. Licholai
Title : Vice President - Medical Affairs
Since: 12/2004
 Earnings Calls
Earnings Release Dates : 13th May 2008 , 29th January 2008
Audio
 Annual Reports
 Quarterly Earnings - FOLD
Sequential Earnings Growth | Quarterly Earnings by Year | Quarterly Earnings Growth by Year

Source: Company filings    Q1:March  Q2:June  Q3:September  Q4:December
 Annual Earnings - FOLD
Annual earnings growth

Diluted EPS Excluding Extraordinary Items     Source: Company filings
 123JUMP News:
Amicus and LDK Solar Trade Down   Jun 04, 3:19 PM EDT
 IPO Reports:
Amicus Therapeutics
The Company’s lead product development programs are Amigal for Fabry disease, AT2101 for Gaucher disease and AT2220 for Pompe disease. The Company is currently conducting Phase II clinical trials of Amigal and expect to initiate Phase I trials for AT2101 in the second half of 2006. The Company’s most advanced product candidate, Amigal, is an orally-administered, small molecule for the treatment of Fabry disease.
More...




   
© 1999-2008 123jump.com. All rights reserved   
 

Warning: Unknown: Your script possibly relies on a session side-effect which existed until PHP 4.2.3. Please be advised that the session extension does not consider global variables as a source of data, unless register_globals is enabled. You can disable this functionality and this warning by setting session.bug_compat_42 or session.bug_compat_warn to off, respectively. in Unknown on line 0